Nūhou ʻOihana

Ua hōʻike ʻia kahi haʻawina haʻahaʻa honua i ka kūleʻa lōʻihi o ka CD19 CAR T-cell therapy i ka mālama ʻana i nā maʻi me ka relapsed/refractory acute lymphoblastic leukemia (ALL) ma hope o ka allogeneic hematopoietic stem cell transplantation, e hāʻawi ana i ka manaʻolana hou i ka hematology.

I loko o nā makahiki he ʻelima i hala iho nei, ua hoʻololi ka noiʻi ʻana i nā cell Natural Killer (NK) i ko mākou ʻike ʻana i ka palekana kūlohelohe, e hāʻawi ana i nā ala hou no ka maʻi kanesa a me nā maʻi viral.

Ua mālama maikaʻi ʻia kahi haʻawina paionia ma Erlangen University Hospital i kahi kaikamahine 16 makahiki me ka systemic lupus erythematosus (SLE) me ka hoʻohana ʻana i ka lāʻau cell CAR-T. Hōʻailona kēia i ka hoʻohana mua ʻana i kēia lāʻau lapaʻau no ka pediatric lupus, e hāʻawi ana i ka manaolana hou no nā keiki me nā maʻi autoimmune.

ʻO kahi haʻawina hou ma Nature Communications e hōʻike ana i nā ʻike koʻikoʻi i nā ala hōʻailona intrinsic e hoʻololi i ka pono o ka hoʻohaʻahaʻa ʻana i ka protein i manaʻo ʻia me ka hoʻohana ʻana i nā PROTAC. Hiki i kēia ʻike ke wehe i ke ala no nā lāʻau lapaʻau ʻoi aku ka maikaʻi no ka maʻi kanesa a me nā maʻi ʻē aʻe.

ʻO ka hōʻoia ʻana i kahi ʻike lapaʻau palekana a ʻoluʻolu no nā poʻe maʻi leukemia e pili ana i ka mālama pono i kēlā me kēia lā, me ka hoʻomaʻemaʻe kaiapuni, ka hoʻomaʻemaʻe pilikino, ka meaʻai, a me ka hoʻoikaika kino. Hāʻawi kēia alakaʻi i nā ʻōlelo aʻoaʻo koʻikoʻi no ka mālama pono i kēlā me kēia lā e kākoʻo i ka hoʻōla.

Hōʻike ʻia kahi noiʻi hou i nā hopena hoʻohiki o ka CD7-targeted chimeric antigen receptor (CAR) T cell therapy i ka mālama ʻana i nā maʻi me ka relapsed a refractory T-cell acute lymphoblastic leukemia (T-ALL) a me T-cell lymphoblastic lymphoma (T-LBL).

E mālama ʻia ka 66th Annual Meeting o ka American Society of Hematology (ASH) mai Dekemaba 7-10, 2024, ma ka San Diego Convention Center, e hōʻike ana i ka noiʻi groundbreaking a me nā holomua i ka hematology.

ʻOiai ke hoʻomau nei nā pilikia i ka ʻoihana a me ka hoʻolaha ʻana, ke kamaʻilio ʻia nei nā palena o CAR-T therapy e kahi ala hou e hoʻohiki ai: Tumor-Infiltrating Lymphocyte (TIL) therapy. Hōʻike kēia holomua i kahi au hou i ka hakakā ʻana i nā maʻi maʻi paʻa.

Hiki ke mālama a hoʻihoʻi hou i ka ʻōnaehana pale e hāʻawi i ke kala lōʻihi a i ʻole hoʻōla i kekahi mau maʻi autoimmune.

Ua mālama ʻia ka 65th Annual Meeting of the American Society of Hematology (ASH) mai 9 a 12 Dekemaba 2023, ma San Diego, USA. E like me ka nui a me ka piha piha o ka hematology kiʻekiʻe o ka hanana hoʻonaʻauao kiʻekiʻe, ua huki ia i nā kaukani o nā loea a me nā loea mai nā wahi āpau ...